Caris Life Sciences, Inc. (CAI) key performance indicators and operating metrics (12 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Gross Margin (GAAP) | 65.00 percent | FY2026-Q1 |
| Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization | 26.2M | FY2026-Q1 |
| Molecular Profiling Services Revenue | 210.8M | FY2026-Q1 |
| Pharma Research and Development Services Revenue | 5.37M | FY2026-Q1 |
| Clinical Therapy Selection Cases | 52.8K | FY2026-Q1 |
| Total Matched Profiles (Cumulative) | 790K | FY2026-Q1 |
| Total Profiles (Cumulative) | 1.07M | FY2026-Q1 |
| Whole Exome Profiles (Cumulative) | 677K | FY2026-Q1 |
| Whole Transcriptome Profiles (Cumulative) | 728K | FY2026-Q1 |
| CARIS Assure Cases | 9.2K | FY2026-Q1 |
| MI Profile Cases | 43.6K | FY2026-Q1 |
| Free Cash Flow | 39.7M | FY2025-Q4 |
Back to CAI overview · CAI earnings · CAI holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.